Oruka Therapeutics (ORKA) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Oruka Therapeutics (ORKA) is set to announce its Q1 2025 earnings on Thursday, August 7th, with analysts expecting a loss of ($0.48) per share.
• The stock price opened at $13.79 and has a 52-week high of $52.32, reflecting a market capitalization of approximately $516.30 million.
• Analysts maintain a predominantly positive outlook on Oruka Therapeutics, with an average rating of "Buy" and target prices ranging from $40 to $45.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) is anticipated to release its Q1 2025 earnings data before the market opens on Thursday, August 7th. Analysts expect Oruka Therapeutics to post earnings of ($0.48) per share for the quarter.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.17. On average, analysts expect Oruka Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Oruka Therapeutics Price Performance

Shares of Oruka Therapeutics stock traded up $0.01 on Friday, reaching $13.60. 142,850 shares of the company were exchanged, compared to its average volume of 159,251. The stock's 50 day moving average price is $12.82 and its 200-day moving average price is $11.38. The company has a market cap of $509.18 million, a P/E ratio of -3.01 and a beta of -0.35. Oruka Therapeutics has a 1-year low of $5.49 and a 1-year high of $52.32.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Oruka Therapeutics stock. Goldman Sachs Group Inc. acquired a new stake in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 244,199 shares of the company's stock, valued at approximately $2,505,000. Goldman Sachs Group Inc. owned 0.65% of Oruka Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 56.44% of the company's stock.

Analyst Ratings Changes

ORKA has been the subject of several recent analyst reports. HC Wainwright restated a "buy" rating and set a $45.00 target price on shares of Oruka Therapeutics in a research note on Wednesday, July 23rd. Wall Street Zen upgraded Oruka Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday, June 22nd. Wedbush restated an "outperform" rating and set a $40.00 target price on shares of Oruka Therapeutics in a research note on Monday, July 21st. Finally, BTIG Research initiated coverage on Oruka Therapeutics in a research note on Thursday, May 22nd. They set a "buy" rating for the company. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $40.38.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.